Your browser doesn't support javascript.
loading
Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review.
Perazzoli, Gloria; García-Valdeavero, Olga M; Peña, Mercedes; Prados, Jose; Melguizo, Consolación; Jiménez-Luna, Cristina.
Afiliação
  • Perazzoli G; Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
  • García-Valdeavero OM; Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18071 Granada, Spain.
  • Peña M; Instituto Biosanitario de Granada (ibs.GRANADA), 18014 Granada, Spain.
  • Prados J; Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
  • Melguizo C; Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
  • Jiménez-Luna C; Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18071 Granada, Spain.
Metabolites ; 13(7)2023 Jul 22.
Article em En | MEDLINE | ID: mdl-37512579
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year survival rates around 10%. The only curative option remains complete surgical resection, but due to the delay in diagnosis, less than 20% of patients are eligible for surgery. Therefore, discovering diagnostic biomarkers for early detection is crucial for improving clinical outcomes. Metabolomics has become a powerful technology for biomarker discovery, and several metabolomic-based panels have been proposed for PDAC diagnosis, but these advances have not yet been translated into the clinic. Therefore, this review focused on summarizing metabolites identified for the early diagnosis of PDAC in the last five years. Bibliographic searches were performed in the PubMed, Scopus and WOS databases, using the terms "Biomarkers, Tumor", "Pancreatic Neoplasms", "Early Diagnosis", "Metabolomics" and "Lipidome" (January 2018-March 2023), and resulted in the selection of fourteen original studies that compared PDAC patients with subjects with other pancreatic diseases. These investigations showed amino acid and lipid metabolic pathways as the most commonly altered, reflecting their potential for biomarker research. Furthermore, other relevant metabolites such as glucose and lactate were detected in the pancreas tissue and body fluids from PDAC patients. Our results suggest that the use of metabolomics remains a robust approach to improve the early diagnosis of PDAC. However, these studies showed heterogeneity with respect to the metabolomics techniques used and further studies will be needed to validate the clinical utility of these biomarkers.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies / Systematic_reviews Idioma: En Revista: Metabolites Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies / Systematic_reviews Idioma: En Revista: Metabolites Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha